Terms: = Lung cancer AND EIF3E, eIF3-p46, 3646, ENSG00000104408, EIF3S6, eIF3e, EIF3-P48, INT6 AND Prognosis
4 results:
1. Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.
Dong Y; Zhou Z; Wang J; Ma L; Liu Z; Wang Y; Song J; Zhang S; Che N
Pathol Res Pract; 2019 May; 215(5):946-951. PubMed ID: 30760406
[TBL] [Abstract] [Full Text] [Related]
2. Effect of previous history of cancer on survival of patients with a second cancer of the head and neck.
Jégu J; Belot A; Borel C; Daubisse-Marliac L; Trétarre B; Ganry O; Guizard AV; Bara S; Troussard X; Bouvier V; Woronoff AS; Colonna M; Velten M
Oral Oncol; 2015 May; 51(5):457-63. PubMed ID: 25687113
[TBL] [Abstract] [Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract] [Full Text] [Related]
4. int6 expression can predict survival in early-stage non-small cell lung cancer patients.
Buttitta F; Martella C; Barassi F; Felicioni L; Salvatore S; Rosini S; D'Antuono T; Chella A; Mucilli F; Sacco R; Mezzetti A; Cuccurullo F; Callahan R; Marchetti A
Clin Cancer Res; 2005 May; 11(9):3198-204. PubMed ID: 15867213
[TBL] [Abstract] [Full Text] [Related]
